发布求助
文献互助 智能选刊 最新文献

Trends in cancer最新文献

筛选
英文 中文
B7-H3: a robust target for immunotherapy in prostate cancer B7-H3：前列腺癌免疫疗法的强大靶点
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-06-04 DOI: 10.1016/j.trecan.2024.05.003
Rafael Pulido, José I. López, Caroline E. Nunes-Xavier
{"title":"B7-H3: a robust target for immunotherapy in prostate cancer","authors":"Rafael Pulido, José I. López, Caroline E. Nunes-Xavier","doi":"10.1016/j.trecan.2024.05.003","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.05.003","url":null,"abstract":"<p>B7-H3, an immune checkpoint glycoprotein, facilitates immune evasion and the promotion of tumors and is highly expressed on the surface of prostate cancer (PCa) cells, which makes it a feasible and robust candidate for immunotherapies against advanced prostate cancer. Here, we summarize and discuss recent findings on the suitability of targeting B7-H3 in PCa treatment.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"40 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141258124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer 将循环肿瘤 DNA 作为可切除非小细胞肺癌的预后生物标记物
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-06-04 DOI: 10.1016/j.trecan.2024.04.004
Chris Abbosh, Darren Hodgson, Gary J. Doherty, Davina Gale, James R.M. Black, Leora Horn, Jorge S. Reis-Filho, Charles Swanton
{"title":"Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer","authors":"Chris Abbosh, Darren Hodgson, Gary J. Doherty, Davina Gale, James R.M. Black, Leora Horn, Jorge S. Reis-Filho, Charles Swanton","doi":"10.1016/j.trecan.2024.04.004","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.04.004","url":null,"abstract":"<p>Systemic treatment of resectable non-small cell lung cancer (NSCLC) is evolving with emerging neoadjuvant, perioperative, and adjuvant immunotherapy approaches. Circulating tumor DNA (ctDNA) detection at clinical diagnosis, during neoadjuvant therapy, or after resection may discern high-risk patients who might benefit from therapy escalation or switch. This Review summarizes translational implications of data supporting ctDNA-based risk determination in NSCLC and outstanding questions regarding ctDNA validity/utility as a prognostic biomarker. We discuss emerging ctDNA capabilities to refine clinical tumor–node–metastasis (TNM) staging in lung adenocarcinoma, ctDNA dynamics during neoadjuvant therapy for identifying patients deriving suboptimal benefit, and postoperative molecular residual disease (MRD) detection to escalate systemic therapy. Considering differential relapse characteristics in landmark MRD-negative/MRD-positive patients, we propose how ctDNA might integrate with pathological response data for optimal postoperative risk stratification.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"30 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141258209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biosocial determinants inform on enduring cancer disparities 生物社会决定因素为癌症的持久性差异提供信息
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-06-04 DOI: 10.1016/j.trecan.2024.05.004
David P. Turner, Robert A. Winn, Victoria J. Findlay
{"title":"Biosocial determinants inform on enduring cancer disparities","authors":"David P. Turner, Robert A. Winn, Victoria J. Findlay","doi":"10.1016/j.trecan.2024.05.004","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.05.004","url":null,"abstract":"<p>Social, environmental, and biological risk factors influence exposures to newly termed ‘biosocial determinants of health’. As molecular factors that lie at the intersection between lived experiences and individual biology, biosocial determinants may inform on the enduring complexity of cancer disparity across transdisciplinary studies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"53 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141258180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging roles of TBK1 in cancer immunobiology. TBK1 在癌症免疫生物学中的新作用。
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-06-01 Epub Date: 2024-03-21 DOI: 10.1016/j.trecan.2024.02.007
Alex Miranda, Carl A Shirley, Russell W Jenkins
{"title":"Emerging roles of TBK1 in cancer immunobiology.","authors":"Alex Miranda, Carl A Shirley, Russell W Jenkins","doi":"10.1016/j.trecan.2024.02.007","DOIUrl":"10.1016/j.trecan.2024.02.007","url":null,"abstract":"<p><p>TANK-binding kinase 1 (TBK1) is a versatile serine/threonine protein kinase with established roles in innate immunity, metabolism, autophagy, cell death, and inflammation. While best known for its role in regulating innate immunity, TBK1 has emerged as a cancer cell-intrinsic immune evasion gene by virtue of its role in modulating cellular responses to inflammatory signals emanating from the immune system. Beyond its effect on cancer cells, TBK1 appears to regulate lymphoid and myeloid cells in the tumor immune microenvironment. In this review, we detail recent advances in our understanding of the tumor-intrinsic and -extrinsic roles and regulation of TBK1 in tumor immunity.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"531-540"},"PeriodicalIF":18.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11168882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140190180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intracranial CAR-T cell delivery in glioblastoma patients. 为胶质母细胞瘤患者提供颅内 CAR-T 细胞。
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-06-01 Epub Date: 2024-05-22 DOI: 10.1016/j.trecan.2024.05.002
Philippa Vaughn-Beaucaire, Moon Jung Choi, Olin Liang, Sean E Lawler
{"title":"Intracranial CAR-T cell delivery in glioblastoma patients.","authors":"Philippa Vaughn-Beaucaire, Moon Jung Choi, Olin Liang, Sean E Lawler","doi":"10.1016/j.trecan.2024.05.002","DOIUrl":"10.1016/j.trecan.2024.05.002","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR)-T cell therapy is emerging as a promising approach for improving outcomes in high-grade glioma. Here, we highlight three recent studies that reported safety and feasibility of intracranial CAR-T cell administration in patients with glioblastoma (GBM) as well as preliminary evidence of potential responses, supporting further investigations of this approach.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"478-480"},"PeriodicalIF":18.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141082303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chromatin as an old and new anticancer target 染色质作为新老抗癌靶点
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-06-01 DOI: 10.1016/j.trecan.2024.05.005
Jacques Neefjes, Katerina Gurova, Jay Sarthy, Gábor Szabó, Steven Henikoff
{"title":"Chromatin as an old and new anticancer target","authors":"Jacques Neefjes, Katerina Gurova, Jay Sarthy, Gábor Szabó, Steven Henikoff","doi":"10.1016/j.trecan.2024.05.005","DOIUrl":"https://doi.org/10.1016/j.trecan.2024.05.005","url":null,"abstract":"<p>Recent genome-wide analyses identified chromatin modifiers as one of the most frequently mutated classes of genes across all cancers. However, chemotherapies developed for cancers involving DNA damage remain the standard of care for chromatin-deranged malignancies. In this review we address this conundrum by establishing the concept of ‘chromatin damage’: the non-genetic damage to protein–DNA interactions induced by certain small molecules. We highlight anthracyclines, a class of chemotherapeutic agents ubiquitously applied in oncology, as an example of overlooked chromatin-targeting agents. We discuss our current understanding of this phenomenon and explore emerging chromatin-damaging agents as a basis for further studies to maximize their impact in modern cancer treatment.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":"102 1","pages":""},"PeriodicalIF":18.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141196353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments. 乳腺癌的抗癌免疫反应：当前和新兴的生物标记物与治疗方法。
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-06-01 Epub Date: 2024-03-22 DOI: 10.1016/j.trecan.2024.02.008
Victoria C Rayson, Michael A Harris, Peter Savas, Michael L Hun, Balaji Virassamy, Roberto Salgado, Sherene Loi
{"title":"The anti-cancer immune response in breast cancer: current and emerging biomarkers and treatments.","authors":"Victoria C Rayson, Michael A Harris, Peter Savas, Michael L Hun, Balaji Virassamy, Roberto Salgado, Sherene Loi","doi":"10.1016/j.trecan.2024.02.008","DOIUrl":"10.1016/j.trecan.2024.02.008","url":null,"abstract":"<p><p>Triple-negative breast cancers (TNBCs) exhibit heightened T cell infiltration, contributing to an enhanced response to immune checkpoint blockade (ICB) compared with other subtypes. An immune-rich immune microenvironment correlates with improved prognosis in early and advanced TNBC. Combination chemotherapy and ICB is now the standard of care in early- and late-stage TNBC. Although programmed death ligand-1 (PD-L1) positivity predicts ICB response in advanced stages, its role in early-stage disease remains uncertain. Despite neoadjuvant ICB becoming common in early-stage TNBC, the necessity of adjuvant ICB after surgery remains unclear. Understanding the molecular basis of the immune response in breast cancer is vital for precise biomarkers for ICB and effective combination therapy strategies.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"490-506"},"PeriodicalIF":18.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140194648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy. 纳米药物辅助基于免疫原性细胞死亡（ICD）的抗癌疗法。
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-06-01 Epub Date: 2024-03-29 DOI: 10.1016/j.trecan.2024.03.003
Robin Demuynck, Yanou Engelen, André G Skirtach, Stefaan C De Smedt, Ine Lentacker, Dmitri V Krysko
{"title":"Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy.","authors":"Robin Demuynck, Yanou Engelen, André G Skirtach, Stefaan C De Smedt, Ine Lentacker, Dmitri V Krysko","doi":"10.1016/j.trecan.2024.03.003","DOIUrl":"10.1016/j.trecan.2024.03.003","url":null,"abstract":"<p><p>Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, several efforts were made to improve the ICD-based therapies. Here, we discuss how nanomaterial-based strategies increase the efficacy of ICD and highlight their benefits and challenges.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"486-489"},"PeriodicalIF":18.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140327203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Puzzling phenomenon: adult-onset cancer predisposition and pediatric cancer. 令人费解的现象：成人致癌倾向与小儿癌症。
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-06-01 Epub Date: 2024-03-19 DOI: 10.1016/j.trecan.2024.02.011
Michaela Kuhlen, Thomas G Hofmann, Monika M Golas
{"title":"Puzzling phenomenon: adult-onset cancer predisposition and pediatric cancer.","authors":"Michaela Kuhlen, Thomas G Hofmann, Monika M Golas","doi":"10.1016/j.trecan.2024.02.011","DOIUrl":"10.1016/j.trecan.2024.02.011","url":null,"abstract":"<p><p>Pathogenic variants (PVs) in DNA repair-linked adult-onset cancer predisposition genes, including double heterozygosity, are increasingly identified in pediatric patients with cancer. Their role in childhood cancer, however, remains poorly understood. Integrating comprehensive tumor analysis is integral for understanding the contribution of such PVs in cancer development and personalized cancer care.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"481-485"},"PeriodicalIF":18.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140176690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lifileucel: the first cellular therapy approved for solid tumours. Lifileucel：首个获准用于实体瘤的细胞疗法。
IF 18.4 1区 医学
Trends in cancer Pub Date : 2024-06-01 Epub Date: 2024-05-09 DOI: 10.1016/j.trecan.2024.04.003
Max Julve, Mark P Lythgoe, James Larkin, Andrew J S Furness
{"title":"Lifileucel: the first cellular therapy approved for solid tumours.","authors":"Max Julve, Mark P Lythgoe, James Larkin, Andrew J S Furness","doi":"10.1016/j.trecan.2024.04.003","DOIUrl":"10.1016/j.trecan.2024.04.003","url":null,"abstract":"<p><p>The US Food and Drug Administration (FDA) approval of lifileucel, for advanced melanoma, represents the first cellular therapy to reach the clinic for solid cancers. Here, we summarise this landmark approval, consider the associated regulatory pathway, and evaluate the challenges that remain to ensure effective implementation of this advanced 'living' therapy.</p>","PeriodicalId":23336,"journal":{"name":"Trends in cancer","volume":" ","pages":"475-477"},"PeriodicalIF":18.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140899685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信